Evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies

References

• GOLD. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management, and prevention of COPD – 2020 report. 2020 [cited 2020 Apr 22]. Available from: https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf.
   Google Scholar
• Cazzola M, Rogliani P, Calzetta L, et al. Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. Eur Respir J. 2018 Dec;52(6):1801586.
   Web of Science ®Google Scholar
• Calzetta L, Cazzola M, Matera MG, et al. Adding a LAMA to ICS/LABA therapy: a meta-analysis of triple combination therapy in COPD. Chest. 2019 Apr;155(4):758–770. .
   PubMed Web of Science ®Google Scholar
• Leung JM, Sin DD. Inhaled corticosteroids in COPD: the final verdict is. Eur Respir J. 2018 Dec;52(6):1801940.
   PubMed Web of Science ®Google Scholar
• Lipworth BJ, Kuo CRW. Single triple vs dual inhaler therapy. Chest. 2019 May;155(5):1078–1079.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Cazzola M, Matera MG, et al. Single triple vs dual inhaler therapy response. CHEST. 2019;155(5):1079–1080. .
   PubMed Web of Science ®Google Scholar
• Rabe KF, Martinez FJ, Ferguson GT, et al., Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 383(1): 35–48. 2020. .
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018 Sep 14;6(10):747–758. .
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018 Apr 18;378(18):1671–1680. .
   PubMed Web of Science ®Google Scholar
• Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016 Sep 03;388(10048):963–973. .
   PubMed Web of Science ®Google Scholar
• Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015 Jan 1;4(1):1.
   PubMed Web of Science ®Google Scholar
• Schardt C, Adams MB, Owens T, et al. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak. 2007 Jun 15;7(1):16.
   PubMed Web of Science ®Google Scholar
• van Valkenhoef G, Lu G, de Brock B, et al. Automating network meta-analysis. Res Synth Methods. 2012 Dec;3(4):285–299. .
   PubMed Web of Science ®Google Scholar
• Calzetta L, Rogliani P, Matera MG, et al. A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD. Chest. 2016 May;149(5):1181–1196. .
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Calzetta L, et al. Impact of mucolytic agents on COPD exacerbations: a pair-wise and network meta-analysis. COPD. 2017 Oct;14(5):552–563. .
   PubMedGoogle Scholar
• Higgins JPT, Savović J, Page MJ, et al. Chapter 8: assessing risk of bias in a randomized trial. In: Cochrane handbook for systematic reviews of interventions version 6.0 (updated July 2019). Cochrane; 2019. p. 205–228. Available from: www.training.cochrane.org/handbook
   Google Scholar
• Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019 Aug 28;366:l4898. .
   PubMed Web of Science ®Google Scholar
• McGuinness LA. Robvis: an R package and web application for visualising risk-of-bias assessments. 2019 [updated 2019 Jul 1]. Available from: https://github.com/mcguinlu/robvis
   Google Scholar
• Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011 Apr;64(4):383–394. .
   PubMed Web of Science ®Google Scholar
• Catala-Lopez F, Tobias A, Cameron C, et al. Network meta-analysis for comparing treatment effects of multiple interventions: an introduction. Rheumatol Int. 2014 Nov;34(11):1489–1496. .
   PubMed Web of Science ®Google Scholar
• Rogliani P, Matera MG, Ora J, et al. The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis. Int J COPD. 2017;12:3469–3485.
   Google Scholar
• Rogliani P, Ritondo BL, Ora J, et al. SMART and as-needed therapies in mild to severe asthma: a network meta-analysis. Eur Respir J. 2020 May 19;2000625. DOI:10.1183/13993003.00625-2020.
   Web of Science ®Google Scholar
• Rogliani P, Matera MG, Ritondo BL, et al. Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations. Pulm Pharmacol Ther. 2019 Sep 11;59:101841. .
   PubMed Web of Science ®Google Scholar
• Smith CM. Origin and uses of primum non nocere–above all, do no harm! J Clin Pharmacol. 2005 Apr;45(4):371–377. .
   PubMed Web of Science ®Google Scholar
• Vanfleteren L, Fabbri LM, Papi A, et al. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal. Int J Chron Obstruct Pulmon Dis. 2018;13:3971–3981.
   PubMed Web of Science ®Google Scholar
• Lipson DA, Dransfield MT, Han MK, et al. Reply to: mortality in IMPACT: confounded by asthma? Am J Respir Crit Care Med. 2020 May 12. DOI:10.1164/rccm.202004-1399LE.
   Google Scholar
• Lipson DA, Crim C, Criner GJ, et al. Reduction in all-cause mortality with fluticasone Furoate/Umeclidinium/Vilanterol in COPD patients. Am J Respir Crit Care Med. 2020 Mar 12;201(12):1508–1516.
   PubMed Web of Science ®Google Scholar
• Suissa S. Mortality in IMPACT: confounded by asthma? Am J Respir Crit Care Med. 2020;202(5):772–773. DOI:10.1164/rccm.202004-1159LE.
   Web of Science ®Google Scholar
• Gaduzo S, McGovern V, Roberts J, et al. When to use single-inhaler triple therapy in COPD: a practical approach for primary care health care professionals. Int J Chron Obstruct Pulmon Dis. 2019;14:391.
   PubMed Web of Science ®Google Scholar